Study sponsor: HealthPartners Institute Cancer Research Center

Location:  HealthPartners Frauenshuh Cancer Center

Phase of Study: Registry / Supportive Care

Purpose of study: The purpose of this study is to look at daily doses of THC and CBD, blood cannabis levels, and changes in patient-reported symptoms, in order to understand if certain dose levels lead to improved symptoms. By determining the appropriate dosages, this will in turn help patients and providers to choose doses that are safe, effective, and cost-efficient.

Inclusion Criteria:
– Adults (aged 18 or more at enrollment)
– Seen in HealthPartners CanCaRE clinic with a cancer diagnosis
– Cannabis-naïve (no cannabis use in past 3 months) with plans to initiate cannabis
– Must be willing to be registered in the Minnesota Medical Cannabis Program (MMCP) and follow all rules and requirements of the state program
– Must be willing to report baseline and required patient-reported outcomes
– Must agree to only use cannabis dispensed from the state’s approved dispensaries

Exclusion Criteria:
– Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis)
– Patients who are pregnant or breastfeeding or plan to become pregnant during the study period. Pregnancy test is not required during the screening period.
– Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance

Study Contact:
Carly Selleck
(952) 993-6723
Carly.Selleck@ParkNicollet.com